Moderna is working on an HIV vaccine after the success of the Covid 19 vaccine.

 

What the innovative mRNA technology used to make the vaccine could do next.

Vaccines using mRNA have potential uses far beyond immunization—to treat cancer, for instance, or addiction, Lynda Stuart, deputy director for vaccines at the Bill and Melinda Gates Foundation, told Quartz. But as new applications for mRNA vaccines are explored, one seems more immediate: other infectious diseases.

A glimpse of what that might look like was provided today by Moderna, the 10-year-old Cambridge, Massachusetts-based company that supplied the technology undergirding Pfizer’s vaccine. The company announced a program to develop vaccines for the seasonal flu, the Nipah virus (a virus that can cause various conditions, including encephalitis), and HIV.

While the research to develop an HIV vaccine has been ongoing since 1987, so far no candidate has been successful. In the past few years, Moderna had been working on possible vaccine candidates, thanks to investment from the Gates Foundation, and is taking two such candidates to the first phase of trials this year.

A successful vaccine would be a groundbreaking development in the quest to eliminate HIV, a virus that kills nearly 700,000 people a year worldwide, particularly in poorer countries where large population groups lack access to medications to stop the progression of the disease.

While the Covid-19 vaccine was developed in record time, Moderna’s announcement shouldn’t raise hopes of similarly rapid development for HIV.  HIV is a much more complex virus than the coronavirus, and it will likely still take years before a vaccine, even an mRNA-based one, is available.

The announcement is important for another reason, as it shows Moderna’s intention of focusing further on vaccines, a market that had once been less than attractive to biotechnology companies because of its long timelines and relatively low revenue prospects. But the success of Covid-19’s vaccine has made the field more interesting to them and opened the door for potentially profitable products, such as the flu vaccine, which has a market of about $4 billion a year. According to a company statement, Moderna is also conducting early-stage research for several other vaccines, including for the Zika virus, and H7N9 influenza.

By Annalisa Merelli

Reporter

January 12, 2021

WhatsApp privacy changes could turn off Saudi users: Cybersecurity experts

 

Some Saudi WhatsApp users said they were now considering other similar messaging app options such as Telegram and Signal. (Shutterstock)

• The new update will require users to share data with Facebook, previously optional

RIYADH: A controversial new WhatsApp privacy policy could see many Saudi users switch off to the Kingdom’s favorite instant messaging app, cybersecurity experts claim.
From Feb. 8, users of the popular mobile social media platform will no longer be able to access the service unless they have accepted the update and will be forced to delete their accounts.
Under the terms of the new policy, Facebook, which owns WhatsApp, will be able to collect users’ data from the app such as their phone number, email address, contacts, location, device ID, user ID, advertising data, purchase history, product interaction, payment info, crash, performance, and other diagnostic data, customer support, and metadata.
As a result, some Saudi WhatsApp users said they were now considering other similar messaging app options such as Telegram and Signal.
Telegram only collects a user’s name, phone number, contacts, and user ID, while Signal just requires a mobile phone number for registration with no link to the individual’s identity.
Saudi cybersecurity expert, Faisal Alomran, told Arab News: “Facebook applications are known for collecting too much personal information about their users, allegedly for the purpose of delivering better user content experiences.
“However, the concern of data privacy is growing on normal users as they become more aware of the consequences of their private data being leaked,” he said.
Alomar added that from a cybersecurity point of view, while the likelihood of breaching a company such as Facebook was low, the impact if it happened, would be “very high” as data gathered by hackers would expose end-user private information.
“Signal is widely considered to be one of the best applications when it comes to data privacy, as it claims to only collect the phone number for user registration,” he said.
According to Global Media Insight, a Dubai-based research company, 26.25 million Saudis use WhatsApp for instant messaging, making up 71 percent of instant messaging users in the Kingdom.
As well as private messaging, WhatsApp is also used for professional purposes in workplaces, schools, and universities.
Sarah Al-Saleh, a university student from Riyadh, told Arab News that WhatsApp was “not optional” for students.
“At the start of almost every class in a semester, we create a WhatsApp group that we use to share notes, updates about class times, dates of quizzes, and so on,” she said.
“Even the instructors will join the groups to make sure we are not cheating and to inform us if classes are canceled so we don’t waste time waiting for them if they’re not going to show. And if a student misses a class, we can help them ensure that they can catch up easily,” she added.
Abdullah Aloudah, a private-sector employee, said: “It’s almost impossible to get work done without WhatsApp. We use it internally, and even clients from outside the company will use it to contact us. No matter how many times I ask them to email me instead of WhatsApp me, they will always prefer to text.
“Apart from the data concerns, I find it so invasive, and it makes it that much harder to separate my work life from my personal one.”
Facebook is no stranger to privacy controversies. The company has repeatedly been accused of data mining, privacy breaches, and selling private data to third parties. It has also been banned in countries such as China, Iran, and Syria.
WhatsApp was founded in 2009 by Jan Koum and Brian Acton, two former Yahoo! executives, as a free alternative to SMS text messages which charged users for each individual message sent.
Facebook announced plans to acquire WhatsApp in February 2014 and paid $21.8 billion, amounting to $55 per user.

 

Saturday .  January 09, 2021

India embarks on one of the world's most ambitious vaccine rollouts after emergency use approval

 (CNN)India is embarking on one of the world's most ambitious mass immunization programs ever undertaken after regulators approved the country's first two Covid-19 vaccines for restricted emergency use.

Indian drug regulators on Sunday gave the go-ahead for two coronavirus vaccines, one developed by AstraZeneca and Oxford University, and the other conceived locally by Bharat Biotech and a government-run institute.

Both vaccines will be administered in two doses and stored at standard refrigerator temperatures of 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit).

The approval is a crucial step in India's effort to contain its coronavirus outbreak, which has infected more than 10 million people, trailing only the United States in total caseload.

The country of 1.35 billion is planning to inoculate 300 million frontline workers, elderly and vulnerable people by August, and preparations have been months in the making.

India plans to vaccinate 300 million people against Covid-19. That's almost the size of the US population

The Serum Institute of India, the world's largest vaccine maker, is producing the AstraZeneca and Oxford vaccines locally, having taken on a huge risk to manufacturing the vaccine months before approval from regulators.

"It's a great day for India and the world because this is going to be the most affordable vaccine, that will be equitably distributed as much as possible across the globe," the institute's CEO Adar Poonawalla told CNN Sunday.

But the vaccines, locally branded Covishield, won't be available to other countries until March or April, as the Indian government has restricted them for export, according to Poonawalla.

"This is not going to go to the private market, private hospitals, and other places right now. We're given a restricted license to only give it and provide it to the government of India because they want to prioritize for the most vulnerable and needy segments first," he said.

Vials of AstraZeneca's Covishield coronavirus vaccine are seen inside a visual inspection machine in a lab at the Serum Institute of India, in Pune, India.

India's coronavirus vaccines are an important alternative for developing countries, which may not be able to afford the more expensive vaccines made in the West, or have the cold storage capacity to transport vaccines that require ultra-cold temperatures, such as the ones developed by Pfizer and Moderna.

In September, the Serum Institute of India pledged to manufacture and deliver 200 million doses for COVAX -- a World Health Organization vaccine alliance set up to ensure fair access to Covid-19 vaccines. But the export of vaccines to "low-and middle-income countries" may not begin until the restrictions ease.

Poonawalla said Covishield would be sold initially to the Indian government for $2.74 per dose -- roughly its production cost. It'll be priced between $3 to $5 per dose for export, and at $13.70 for the private market, he added.

Mass vaccination drive

The Serum Institute of India is expecting to sign a formal deal with the Indian government "imminently," and people will start getting vaccinated in the "next seven to 10 days," Poonawalla said.

The institute has already stockpiled 50 million doses of the vaccine ready for distribution this month and is ready to send them to 30 to 40 government locations across the country. From there, they'll be distributed to the smaller centers and clinics that have been set up, he said.

India already has a vast, established network under its Universal Immunization Program, which inoculates about 55 million people per year. Analysts have said that means the country's health system is relatively well geared up for the Covid-19 vaccinations.

Ahead of the mass vaccination drive, the Indian government has also been recruiting and training additional vaccinators and ramping up its stocks of cold-chain storage equipment such as walk-in coolers and freezers, deep freezers, and ice-lined refrigerators over the past few months.

An Indian health official takes part in a dry run for Covid-19 vaccinations at an Urban Community Health Centre in Ajmer, Rajasthan, India on January 2.

On Saturday, it conducted a nationwide Covid-19 vaccine drill at 286 sites across India to familiarize officers on all levels with the operation guidelines, according to the Ministry of Health.

Some 114,100 workers have been trained on tasks such as verifying personal data, conducting cold chain and logistics management, and uploading information using government software, the ministry said in a statement.

Lack of data

India's drug regulator also approved Covaxin, the country's first homegrown coronavirus vaccine developed jointly by Bharat Biotech and the government-run Indian Council of Medical Research.

But the government has faced heated criticism from experts and opposition leaders for not revealing the vaccine's efficacy results or any other data from its clinical trials.

Following Sunday's announcement, Congress leader Shashi Tharoor said on Twitter that Covaxin's approval was "premature and could be dangerous" because it has not completed Phase 3 trials.

"Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime," he tweeted.

Dr. Randeep Guleria, director of the All India Institute of Medical Sciences, agreed.

"I would say that we should in the first phase focus predominantly on the Serum Institute of India -- the Astra Zeneca vaccine, and the Bharat Biotech is only as a standby or a backup in case there is a surge in the number of cases," said Guleria, a member of the national task force on Covid-19 management.

Governor of the eastern Indian state of West Bengal Jagdeep Dhankhar (center) at the launch of the third phase of the regulatory trial of COVAXIN in December 2020.

Following the criticism, India's health minister Dr. Harsh Vardha tweeted late on Sunday that the emergency use authorization (EUA) for Covaxin is "differently conditional -- in clinical trial mode."

"EUA for COVAXIN is different from COVISHIELD because its use will be in clinical trial mode. All COVAXIN recipients to be tracked, monitored as if they're in trial," he wrote.

In a news release Sunday, Bharat Biotech said its Phase 3 clinical trial for Covaxin started in mid-November, with a goal to include 26,000 volunteers.

"COVAXIN™ has been evaluated in approximately 1000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogenicity results, with acceptance in international peer-reviewed scientific journals," the release said.

Vaccine rollouts in Asia

Across Asia, a growing number of countries have started vaccinations against Covid-19.

In China, regulators last week approved the country's first homegrown coronavirus vaccine, developed by state-owned pharmaceutical giant Sinopharm.

China approves Sinopharm Covid-19 vaccine, promises free shots for all citizens

The Chinese government aims to inoculate 50 million people against Covid-19 ahead of February's Lunar New Year celebrations. The country has already administered 4.5 million doses of experimental Chinese vaccines since June under its emergency use program, which included frontline workers such as health care workers and customs officers.

The next step is to inoculate vulnerable groups such as the elderly and people with underlying diseases, before vaccinating the general population, officials said last week.

In Beijing, the municipal government started vaccinating targeted groups of the population, including frontline workers and students and employees who need to go overseas, on January 1. It has set up 220 vaccination sites across the city and inoculated 73,500 people as of Saturday.

Compared with the swift rollouts in India and China, the Japanese government has faced criticism over its slowness in rolling out the vaccines.

Japanese Prime Minister Yoshihide Suga told a news conference Monday that Covid-19 vaccinations will begin in late February. He said frontline medical workers and the elderly would be the first groups to receive the vaccinations, adding that the government has moved forward the timeline amid a surge in coronavirus cases.

SARS-CoV-2 transmission role of mask in classroom setting

The University of Wisconsin-Madison has conducted a study showing that wearing facemasks in the classroom setting can be highly effective at reducing the aerosol transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

Study: Strategies to minimize SARS-CoV-2 transmission in classroom settings: Combined impacts of ventilation and mask effective filtration efficiency. Image Credit: Syda Productions / Shutterstock

However, the filtration efficiency of facemasks can below if they are not fitted properly, warns David Rothamer and colleagues.

The researchers also demonstrated that classroom ventilation alone did not sufficiently reduce the infection probability, whereas even the use of only moderately effective facemasks did reduce this probability sufficiently.

"The results reinforce the use of properly donned masks to achieve reduced aerosol transmission of SARS-CoV-2 and other infectious diseases transmitted via respiratory aerosol indoors," writes the team.

A pre-print version of the paper is available on the medRxiv* server while the article undergoes peer review.

(a) Classroom space setup with manikins (a) view from the front of the room looking back and (b) from the back of the room looking forward.

Using the Wells-Riley equation to assess aerosol transmission

Since the first cases of SARS-CoV-2 were identified in Wuhan, China late last year (2020), researchers have increasingly recognized the long-range airborne route of viral transmission and the need for effective measures to block this transmission mode.

A common approach for assessing long-range airborne transmission (referred to hereafter as aerosol transmission), uses the Wells-Riley equation to relate aerosol concentrations to infection probability.

This approach has already been widely applied in studies of SARS-CoV-2, particularly in the context of super-spreader events.

The researchers say the application of the Wells-Riley equation is useful for risk assessment and the planning of interventions to reduce the risk of disease transmission.

"One of the aims of this paper is to provide recommendations that, when implemented, can decrease the likelihood of COVID-19 transmission in traditionally high occupancy spaces such as classrooms," they write.

What did the researchers do?

The team applied the Wells-Riley equation to evaluate the effect of ventilation, mask filtration, and a combination of the two on aerosol SARS-CoV-2 infection probability in the classroom setting.

Images of masks installed on a manikin for filtration testing (a) 4-layer knit cotton mask, (b) EOC mask, (c) procedure mask, and (d) surgical mask

Related Stories

• Loss of taste and smell may be the most reliable COVID-19 symptoms for digital surveillance
• SARS-CoV-2 spike-antibody binding strength and hydrogen bond numbers are temperature dependent, study finds
• Researchers find a correlation between consistent mask-wearing and improved well-being

A polydisperse neutralized salt (NaCl) aerosol that was generated in a size range consistent with SARS-CoV-2-containing bioaerosols was used as a safe surrogate for measurements.

The mask effective filtration efficiency was tested by seeding a classroom with the NaCl aerosol and sampling concentrations of the aerosol through four different mask types that had been fitted to manikins with and without using mask fitters.

Two of the masks were washable reusable masks. One was made of 4-layers of knit cotton, and the other was made of 3-layers of non-woven spun-bond polypropylene.

The other two masks were disposable. One was a common single-use disposable mask (referred to hereafter as procedure mask), and the other was an ASTM F2100 level-2 surgical mask.

The importance of masks fitting properly

Measurements of the mask's effective filtration efficiency demonstrated the importance of masks being fitted properly. Poorly fitting masks exhibited filtration efficiencies that decreased by as much as a factor of six. The estimated leakage rate for most of the poorly fitted masks was typically more than 50%.

The analysis also found that the knit-cotton mask was only able to achieve an effective filtration efficiency of 26%, even when a mask fitter was used.

In all other cases, the use of a mask fitter significantly improved the effective filtration efficiency, with the exception of the polypropylene mask, which achieved a good fit without a mask fitter. In the case of the procedure mask, the use of a mask fitter achieved effective filtration efficiencies of almost 95%.

Classroom ventilation alone was insufficient

The study also suggested that classroom ventilation alone was not sufficient to achieve infection probabilities of less than 1%.

On the other hand, the use of moderate-to-high effective filtration efficiency masks by all individuals (manikins) present significantly reduced the infection probability.

Depending on the type of mask and whether a mask fitter was used, infection probability was reduced by 5-, 10- or even more than 100-fold.

The team says infection probabilities of less than 0.1% and even lower than 0.0001% could be reached with the use of masks and mask fitters alone.

What does the team advise?

Rothamer and colleagues say the results reinforce the use of properly donned masks to achieve reduced aerosol transmission of SARS-CoV-2.

"The results specifically emphasize the large potential for effective mask-wearing and improved masks, or use of mask fitters, to greatly reduce infection probabilities," concludes the team.

*Important Notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:

• Rothamer D, et al. Strategies to minimize SARS-CoV-2 transmission in classroom settings: Combined impacts of ventilation and mask effective filtration efficiency. medRxiv, 2020.  https://www.medrxiv.org/content/10.1101/2020.12.31.20249101v1

OBESITY

What Causes Obesity?

"What causes a person to become obese?"

Obesity occurs when, over a long period of time, the amount of food we put into our bodies each day is not used. In essence, this means that there consistently is more energy going in, than out. That energy has to go somewhere, so our bodies store it as fat.

Energy In vs Energy Out Equation

ENERGY "IN" MORE THAN ENERGY "OUT" = WEIGHT GAIN.

ENERGY "IN" LESS THAN ENERGY "OUT" =WEIGHT LOSS.

We all overindulge every now and then, and it isn’t this occasional overeating that causes obesity; obesity is caused when we overdo it most days, for a sustained period of time.

Unfortunately, we live in an environment that encourages us to eat and discourages us to be active, making it very easy to gain weight.  

Have a think about it…

Food is readily available, 24 hours a day, 7 days a week Portion sizes and plates are much bigger than they have been before we can get almost anywhere without having to walk or use a bikeTVs, computers and mobile phones encourage a more sedentary lifestyle.

Smoking Ban Reduces Childhood Asthma Hospital Admissions

September 16, 2010 — A ban on smoking in public places in Scotland, instituted in March 2006, has reduced the rate of hospital admissions for childhood asthma, new research findings suggest.
Daniel Mackay, PhD, from the University of Glasgow, in Scotland, and colleagues reported the findings in the September 16 issue of the New England Journal of Medicine.
According to the researchers, the Smoking, Health and Social Care (Scotland) Act banned smoking in all enclosed public places and workplaces in Scotland as of March 26, 2006.
"The legislation has been extremely successful in its primary aim of reducing exposure to environmental tobacco smoke in public places, such as bars," the authors note. In addition, the legislation has reduced exposure of children to environmental tobacco smoke, despite concerns of smoking being displaced to the home, but it is unclear whether the risk for childhood asthma has also decreased.
The researchers collected routine hospital administrative data and ascertained all hospital admissions for asthma in Scotland from January 2000 through October 2009 among children younger than 15 years.
Before the smoking ban, asthma admissions were increasing by an average of 5.2% per year (95% confidence interval [CI], 3.9% - 6.6%). After the ban, the rate of admissions decreased by 18.2% per year relative to the rate on March 26, 2006 (95% CI, 14.7% to 21.8%; P < .001). Rates were reduced both in preschool and school-age children.
Various factors including age group, sex, urban or rural residence, region, or quintile of socioeconomic status had no effect on the outcome.
Limitations of the study include that only exacerbations severe enough to warrant hospitalization were included. In addition, information regarding individual smoking status was not available; therefore, whether the observed reduction in asthma was a result of reduced exposure to environmental tobacco smoke in the home, reduced exposure to environmental tobacco smoke in public places, a reduction in active smoking among school-age children, or an unrelated cause cannot be determined.
"After the introduction of comprehensive smoke-free legislation, there was a reduction in the incidence of asthma among people who did not have occupational exposure to environmental tobacco smoke," the authors conclude.
They add that the "overall exposure of children to environmental tobacco smoke, measured objectively with the use of salivary cotinine concentrations, has fallen since the implementation of the Scottish legislation."
The study was supported by a project grant from National Health Services Health Scotland. One author reports individual employment by National Health Services Scotland; another chairs the Committee on Medical Effects of Air Pollution for the UK Department of Health. The other authors have disclosed no relevant financial relationships.
N Engl J Med. 2010;363:1139-1145.

Nearly Half of Infected US Gay and Bisexual Men Unaware They Have HIV

September 24, 2010 — One in 5 gay and bisexual men in major cities in the United States is infected with HIV, and nearly half — 44% — do not know their status. Most unaware are young and minority men who have sex with men (MSM), according to a new analysis published in the September 24 issue of the Morbidity and Mortality Weekly Report.
"[MSM] are at increased risk for infection with [HIV]," write A. Smith, MPH, and colleagues from the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, US Centers for Disease Control and Prevention (CDC). "In 2006, 57% of new HIV infections in the United States occurred among MSM."
The CDC uses the National HIV Surveillance system (NHBS) to monitor prevalence and trends in HIV-related risk behaviors, HIV testing, and use of HIV prevention services among high-risk populations. In the current report, the authors summarize NHBS data from 2008.
From January to December 2008, 8153 MSM from 21 cities were interviewed and tested for HIV. The study found that the overall prevalence of HIV was 19%.
Non-Hispanic blacks had the highest prevalence (28%), followed by Hispanics (18%), non-Hispanic whites (16%), and persons who were multiracial or of other race (17%).
Forty-four percent of those infected with HIV were unaware of their status. Black MSM with HIV were least likely to be aware of their infection (59%), followed by Hispanic MSM (46%) and white MSM (26%).
The study also found that although young men, aged 30 years or younger, had a lower HIV prevalence than older men, they were much more likely to be unaware of their HIV infection. Among men aged 18 to 29 years who had HIV, 63% were unaware vs 37% of men aged 30 years and older.
Also among young men, MSM of color were less likely than their white counterparts to know they were infected with HIV. Among blacks aged 30 years or younger, 71% were unaware of their status compared with 63% of young Hispanic MSM and 40% of young white MSM.
The study also found a strong link between socioeconomic status and HIV infection in MSM. The prevalence of HIV infection increased as education and income decreased, as did awareness. These findings are similar to those found in recent NHBS research among homosexuals, the authors report.
Men who know their current HIV infection status can be referred to appropriate medical care and prevention services. Once they are linked to prevention services, they can learn ways to avoid transmitting HIV to others, the authors note, adding that efforts to reach out to young and minority MSM should be increased to promote testing for HIV.
The authors also note limitations of their report. Because interviewers conducted the surveys, positive HIV status might have been underreported. Also, because the findings are limited to men who frequented bars, dance clubs, and other MSM venues, they may not be representative of results for all MSM.
"The high proportion of MSM unaware of their HIV infection continues to be a serious public health concern, because these MSM account for the majority of estimated new HIV transmissions in the United States," the author write in their concluding remarks. "The 2008 NHBS data show that MSM remain a key target of strategies to reduce HIV incidence and decrease racial and socioeconomic disparities in the United States."
"This study's message is clear: HIV exacts a devastating toll on [MSM] in America's major cities, and yet far too many of those who are infected don't know it," Kevin Fenton, MD, director of the CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, said in a statement. "We need to increase access to HIV testing so that more MSM know their status, and we all must bring new energy, new approaches, and new champions to the fight against HIV among [MSM]."
The authors have disclosed no relevant financial relationships.
Morb Mortal Wkly Rep. 2010;59:1201-1207

Depression Plus Heart Disease a Particularly Lethal Combination

September 16, 2010 — Patients who have both coronary heart disease (CHD) and depression have a significantly higher risk of dying than patients who have just 1 of these conditions, according to new research published online September 16 in Heart.
Compared with patients without depression and CHD, the risk for all-cause mortality was 3 times higher, and the risk for cardiovascular disease mortality 4 times higher, in patients who had both, after adjusting for age and sex, report Hermann Nabi, MD, from Hôpital Paul-Brousse, Villejuif, Paris, France, and colleagues.
"This study provides further evidence that the relationship between depression and morbidity–mortality is real," Dr. Nabi told Medscape Medical News.
Depression and mortality have been studied separately in patients with CHD and in healthy patients, but this does not allow comparisons across risk-factor groups according to depression and CHD status.
In the study, Dr. Nabi and his team examined the effects of both on mortality in 5936 middle-aged men and women whose mental and physical health were followed-up for a mean of 5.6 years.
The study population was part of the Whitehall II cohort study, a longitudinal study established in 1985 to examine the effect of social and economic factors on the long-term health of 10,308 civil servants who were aged between 35 and 55 years at the start of the study.
Of the 5936 individuals, 170 died during follow-up; 47 of those deaths were from cardiovascular disease.
The analysis showed that the prevalence of depression was 14.9%, and participants with a history of CHD were more likely to have depressive symptoms (20% vs 14%; P = .001) than those without CHD.
The age- and sex-adjusted hazard ratios for all-cause mortality were 1.67 (P < .05) for participants with CHD only, 2.10 (P < .001) for those with depressive symptoms only, and 4.99 (P < .001) for those with both CHD and depressive symptoms compared with participants who were free of both conditions.
Need for a More Integrated Approach
The study findings have implications for research and clinical practice, Dr. Nabi said.
"For research, this study shows that the mechanisms underlying the association between depression and adverse health outcomes such as mortality are still in need of comprehensive studies."
For clinical practice, it implies the need for a more integrated approach in the healthcare system and a shift toward a more "mind–body medicine' approach.
An important step would be to identify cardiac patients who also have depression, he said.
"In this study, the depression worsened heart disease, because we observed that participants with both depression and heart disease were at increased risk for death when compared with those with heart disease only. So we should identify those cardiac patients who have clinically significant depressive symptoms."
Dr. Nabi expressed the wish that his study findings will prompt clinicians to be aware of and look for depression in their patients with heart disease.
"Even though there is no consensus at the moment, healthcare professionals should screen and treat, or refer to treatment. Simple screening tools exist, and [clinicians] should refer their depressed patients, particularly if an adequate referral for systematic depression assessment and treatment is readily available."
He also discussed some limitations of the study.
"This study is based on a cohort of civil servants and did not include blue-collar workers, unemployed, or individuals with precarious jobs. This may have underestimated the magnitude of associations observed in our study because of the prevalence of depression and the mortality rate is higher in these latter individuals. Thus, it is reasonable to assume that the effect of depression would be greater in studies including various populations."
Randomized Trial Required
"This paper is adding to a literature that is imperfect. It makes you feel more confident about the literature," Alexander H. Glassman, MD, chief of clinical psychopharmacology at New York State Psychiatric Institute and professor of psychiatry at Columbia University, New York City, commented to Medscape Medical News.
"There are literally a hundred, maybe more, studies indicating that depression and heart disease are related," Dr. Glassman, who was not part of the current study, noted. "There are a handful of studies that do not find a relationship, but they are vastly outnumbered by the ones that have found a relationship."
However, he pointed out, just because there is an association that does not mean one condition causes the other. The way to prove cause would be with a randomized controlled trial.
"It's very easy to think depression is increasing the risk or is a cause of subsequent heart disease. And let me say, I think it is," said Dr. Glassman, who led the placebo-controlled Sertraline Antidepressant Heart Attack Randomized Trial (SADHART), as reported by Medscape Medical News.
SADHART found that patients hospitalized for acute coronary syndrome who also have major depression are twice as likely to die within 7 years if their depression did not significantly improve.
"The best way to know for sure would be to do a randomized trial on the treatment for depression with a placebo control. If you reduced the depression and those people with an antidepressant effect had a lower mortality, then you would have unequivocal evidence that depression is causing death, because by getting rid of it, you reduce the chance of dying."
The study was funded by the Medical Research Council, British Heart Foundation, Health and Safety Executive, Department of Health, National Heart Lung and Blood Institute, National Institute on Aging, Agency for Health Care Policy Research, and John D. and Catherine T. MacArthur Foundation Research Networks on Successful Midlife Development and Socio-economic Status and Health. Dr. Nabi has disclosed no relevant financial relationships. Dr. Glassman reports financial relationships with Pfizer Inc.
Heart. Published online September 16, 2010.

Women With Low Sexual Arousal May Have Symptom Changes With Placebo Treatment

September 17, 2010 — A large proportion of women with female sexual arousal disorder (FSAD) have clinically significant symptom changes after receiving placebo, according to the results of a secondary data analysis from a randomized controlled trial reported online September 16 in the Journal of Sexual Medicine.
"In clinical trials of drug treatments for women's sexual dysfunction, placebo responses have often been substantial," write Andrea Bradford, PhD, from Baylor College of Medicine in Houston, Texas, and Cindy M. Meston, PhD, from the University of Texas at Austin. "However, little is known about the clinical significance, specificity, predictors, and potential mechanisms of placebo response in sexual dysfunction."
The goal of the study was to evaluate the characteristics and predictors of sexual function outcomes in 50 women with FSAD who were randomly assigned to the placebo group of a 12-week, multisite, controlled pharmaceutical trial. Magnitude, domain specificity, and clinical significance of sexual function scores were evaluated at baseline and at 4, 8, and 12 weeks (after study completion).
Change with time in sexual function outcomes was assessed in relationship to several variables, including age and symptom-related distress at baseline, as well as changes in frequency of sexual behavior during the trial. The primary study endpoint was the total score on the Female Sexual Function Index.
"It's important to note that, even though these women received placebo, they all had an opportunity to talk to a health provider about their difficulties and were asked to closely monitor their sexual behavior and feelings over a 12-week period," Dr. Bradford said in a news release. "Just taking part in this study probably started some meaningful conversations."
Approximately one third of women receiving placebo had a clinically significant magnitude of change after study completion, with similar effect sizes across multiple aspects of sexual function. Although symptom improvement was strongly associated with the frequency of satisfying sexual encounters (SSEs) during treatment, there was significant variation between participants in the association between frequency of sexual encounters and outcome.
"Our study shows that even a limited intervention can have a positive effect in many women with sexual dysfunction," Dr. Bradford said. "This comes as no surprise to sex therapists, but it does suggest a need to investigate behavioral factors more closely in clinical trials."
Limitations of this study include observational design, precluding determination of causality; and the possibility that SSE frequency was just a proxy for another variable, such as changes in general relationship functioning. In addition, the retrospective analysis prevented direct manipulation of variables of interest, and it is not known whether trial participants who received no treatment would have reported the same effects as participants who received placebo.
"A substantial number of women experienced clinically significant improvement in sexual function during treatment with placebo," the study authors write. "Changes in sexual behavior during the trial, more so than participant age or symptom severity at baseline, appeared to be an important determinant of outcome. Contextual and procedural aspects of the clinical trial may have influenced outcomes in the absence of an active drug treatment."
Eli Lilly/ICOS shared the data set used in this study. This study was supported in part by the Houston VA HSR&D Center of Excellence. The views expressed in the journal article are those of the study authors and do not necessarily represent the views of the Department of Veterans Affairs. Drs. Bradford and Meston have disclosed no relevant financial relationships.
J Sex Med. Published online September 16, 2010.

Weight Control and Exercise Could Prevent 20% of Colon Cancer

September 16, 2010 — Around 20% of colon cancer in European countries could be prevented if the whole population managed to reach optimum levels of weight and physical activity, suggest new projections.
The data are reported in the September issue of the European Journal of Cancer, which is dedicated to cancer prevention.
An increasing proportion of the European population now has a body mass index (BMI) higher than 25 kg/m², and few Europeans are engaging in the amounts of physical activity recommended by current guidelines (at least 30 minutes of moderate-intensity activity 5 or more days a week), the researcher note.
The researchers set out to predict what would happen if the European population managed to maintain a mean BMI of 21 kg/m² and if all countries had a level of physical activity similar to that seen in the Netherlands, where both cycling and walking are popular.
They used the PREVENT statistical modeling method, which was developed at Erasmus University in the Netherlands and is frequently used in the European Union's EUROCADET project.
"We know that large numbers of colon cancer cases could be avoided by reducing exposure to risk factors," said senior author Andrew Renehan, PhD, FRCS, FDS, from the School of Medicine, University of Manchester, United Kingdom. And 2 of the most easily controllable risk factors are physical inactivity and excess weight, he added.
"The predictive modeling is beginning to tease out the independent relevance of each of these factors in the prevention of colon cancer," he said in a statement.
"Preventing weight gain and encouraging weight reduction seem to be most beneficial in men, but for women a strategy with a greater emphasis on increasing physical activity would be more effective," he explained.
Colon Cancer Increasing
Colon cancer rates are increasing in Europe; they have been on the rise since 1975. It is the second most common cancer in Europe and the second most common cause of cancer death, the researchers note.
In a previous study, Dr. Renehan and colleagues attributed the increasing rates of all cancers to increasing obesity in European countries. They estimated that in 2008, new cancers attributed to excess body weight affected 3.2% of women and 8.6% of men; this was an increase from the estimates for 2002, which projected that excess weight was related to new cancers in 2.5% of men and 4.1% of women.
Those data were presented at the 2009 meeting of the European Cancer Organization, and reported by Medscape Medical News at the time.
"People in Europe are gaining weight," Dr. Renehan said at the time, "and it is projected to keep rising."
In the new study, the researchers used the computer model to look at what would happen if Europeans continued to grow fatter, using a hypothetical scenario in which obesity levels increased at the same rate as they have in the United States. They predicted that this would lead to an increase in the number of new colon cancer cases of between 0.7% and 3.8%, depending on the European country.
Then they hypothesized a scenario in which Europeans managed to control their weight and managed to achieve an optimum BMI of 21 kg/m². They calculated that by the year 2040, this weight-control strategy would prevent between 2% and 18% of colon cancer cases across the countries they studied. The benefits were much higher for males (13.5% to 18%) than for females (2.3% to 4.6%), and most benefit would be seen in British males (in whom 18% of new colon cancer cases could be prevented).
This "underlines the importance of stopping and reversing the ongoing increase in overweight and obesity prevalence," the authors note.
When the team considered physical activity, they found that the Netherlands had the highest rates, which they attributed to a high frequency of bike use, often as a means of transportation. They also found high levels of walking.
Using the Netherlands as the ideal, the researchers predicted what would happen if other countries adopted the same amount of physical activity. They found that overall, 17.5% of new colon cancer cases could be prevented by 2040, with the most benefit in Spanish females (in whom 21% of new colon cancer cases could be prevented).
"We can safely say that increasing physical activity across Europe to the level already achieved in the Netherlands, where everyone cycles, would be of substantial benefit," said coauthor Jan-Willem Coebergh, MD, PhD, from Erasmus University.
"In summary, the changes in physical activity and/or mean levels of overweight in the selected European populations would result in quite substantial effects on future colon cancer rates," the authors conclude.
The researchers have disclosed no relevant financial relationships.
Eur J Cancer. 2010;46:2605-2616.